{
    "status": "ok",
    "totalResults": 148,
    "articles": [
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "United Therapeutics : Material Event - Form 8-K",
            "description": "(marketscreener.com) \n Item 8.01. Other Events.\n \n \n \n As of November 27, 2023, United Therapeutics Corporation entered into an amendment extending the term of its exclusive license agreement with Eli Lilly and Company covering the U.S. marketing, promotion, \u2026",
            "url": "https://www.marketscreener.com/quote/stock/UNITED-THERAPEUTICS-CORPO-11262/news/United-Therapeutics-Material-Event-Form-8-K-45460757/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-29T11:06:21Z",
            "content": "Item 8.01. Other Events.\r\nAs of November 27, 2023, United Therapeutics Corporation entered into an amendment extending the term of its exclusive license agreement with Eli Lilly and Company (\"Lilly\")\u2026 [+498 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research Nester",
            "title": "Genome Editing Market revenue to hit USD 69.6 Billion by 2036, says Research Nester",
            "description": "Leading genome editing market players include Merck KGaA, Horizon Discovery Ltd., Lonza Group Ltd., Twist Bioscience Corporation, Akron Biotech., CRISPR Therapeutics, Sangamo Therapeutics, Editas Medicine, Intellia Therapeutics, Inc., and Setsuro Tech Inc. Le\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/14/2779817/0/en/Genome-Editing-Market-revenue-to-hit-USD-69-6-Billion-by-2036-says-Research-Nester.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/77e335b1-e272-4a4c-a0ff-211ce0caee29",
            "publishedAt": "2023-11-14T10:30:00Z",
            "content": "New York, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The global genome editing market size is slated to expand at ~21.1% CAGR between 2024 and 2036. The market is poised to garner a revenue of USD 69.6 billio\u2026 [+10290 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Financial Survey: Tiziana Life Sciences (NASDAQ:TLSA) versus United Therapeutics (NASDAQ:UTHR)",
            "description": "Tiziana Life Sciences (NASDAQ:TLSA \u2013 Get Free Report) and United Therapeutics (NASDAQ:UTHR \u2013 Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, \u2026",
            "url": "https://www.etfdailynews.com/2023/11/26/financial-survey-tiziana-life-sciences-nasdaqtlsa-versus-united-therapeutics-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-11-26T11:30:42Z",
            "content": "Tiziana Life Sciences (NASDAQ:TLSA \u2013 Get Free Report) and United Therapeutics (NASDAQ:UTHR \u2013 Get Free Report) are both medical companies, but which is the better business? We will compare the two bus\u2026 [+5680 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Burney Co.",
            "description": "Burney Co. decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 1.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,664 shares of the biotechnology company\u2019s stock afte\u2026",
            "url": "https://www.etfdailynews.com/2023/11/16/united-therapeutics-co-nasdaquthr-shares-sold-by-burney-co/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-11-16T15:12:47Z",
            "content": "Burney Co. decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 1.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund \u2026 [+7028 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Covestor Ltd Buys 267 Shares of United Therapeutics Co. (NASDAQ:UTHR)",
            "description": "Covestor Ltd increased its stake in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 29.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,174 shares of the biotechnology compa\u2026",
            "url": "https://www.etfdailynews.com/2023/11/21/covestor-ltd-buys-267-shares-of-united-therapeutics-co-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-11-21T17:50:51Z",
            "content": "Covestor Ltd increased its stake in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 29.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commis\u2026 [+6860 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by BlackRock Inc.",
            "description": "BlackRock Inc. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 7.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,096,685 shares of the biotechnology company\u2019s stock after\u2026",
            "url": "https://www.etfdailynews.com/2023/12/03/united-therapeutics-co-nasdaquthr-shares-acquired-by-blackrock-inc/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-12-03T13:04:43Z",
            "content": "BlackRock Inc. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 7.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned\u2026 [+6551 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Edgestream Partners L.P. Invests $896,000 in United Therapeutics Co. (NASDAQ:UTHR)",
            "description": "Edgestream Partners L.P. bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) during the 2nd quarter, Holdings Channel reports. The firm bought 4,061 shares of the biotechnology company\u2019s stock, valued at approximately $896,0\u2026",
            "url": "https://www.etfdailynews.com/2023/11/22/edgestream-partners-l-p-invests-896000-in-united-therapeutics-co-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-11-22T13:39:22Z",
            "content": "Edgestream Partners L.P. bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) during the 2nd quarter, Holdings Channel reports. The firm bought 4,061 shares of the b\u2026 [+6466 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Artal Group S.A.",
            "description": "Artal Group S.A. cut its stake in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 9.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,971 shares of the biotechnol\u2026",
            "url": "https://www.etfdailynews.com/2023/11/22/united-therapeutics-co-nasdaquthr-shares-sold-by-artal-group-s-a/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-11-22T16:46:50Z",
            "content": "Artal Group S.A. cut its stake in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 9.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Com\u2026 [+6683 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Renaissance Technologies LLC Has $482.83 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)",
            "description": "Renaissance Technologies LLC decreased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 1.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,187,214 shares of the biotechnology company\u2019s \u2026",
            "url": "https://www.etfdailynews.com/2023/11/29/renaissance-technologies-llc-has-482-83-million-stock-holdings-in-united-therapeutics-co-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-11-29T16:41:11Z",
            "content": "Renaissance Technologies LLC decreased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 1.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The\u2026 [+7013 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "International Biotechnology Trust PLC Boosts Stake in United Therapeutics Co. (NASDAQ:UTHR)",
            "description": "International Biotechnology Trust PLC increased its stake in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 85.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 52,759 shares \u2026",
            "url": "https://www.etfdailynews.com/2023/11/07/international-biotechnology-trust-plc-boosts-stake-in-united-therapeutics-co-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-11-07T15:34:50Z",
            "content": "International Biotechnology Trust PLC increased its stake in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 85.1% during the second quarter, according to its most recent filing with the Secur\u2026 [+7157 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Equities Analysts Issue Forecasts for United Therapeutics Co.\u2019s Q1 2024 Earnings (NASDAQ:UTHR)",
            "description": "United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) \u2013 Stock analysts at Zacks Research raised their Q1 2024 EPS estimates for shares of United Therapeutics in a research report issued on Wednesday, November 29th. Zacks Research analyst K. Shah now expects tha\u2026",
            "url": "https://www.etfdailynews.com/2023/12/01/equities-analysts-issue-forecasts-for-united-therapeutics-co-s-q1-2024-earnings-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-12-01T12:28:57Z",
            "content": "United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) \u2013 Stock analysts at Zacks Research raised their Q1 2024 EPS estimates for shares of United Therapeutics in a research report issued on Wednesday, N\u2026 [+6975 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Portolan Capital Management LLC",
            "description": "Portolan Capital Management LLC lessened its position in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 57.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3\u2026",
            "url": "https://www.etfdailynews.com/2023/12/04/united-therapeutics-co-nasdaquthr-shares-sold-by-portolan-capital-management-llc/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-12-04T17:06:43Z",
            "content": "Portolan Capital Management LLC lessened its position in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 57.0% during the second quarter, according to the company in its most recent 13F filing\u2026 [+6774 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "B. Metzler seel. Sohn & Co. AG Acquires Shares of 908 United Therapeutics Co. (NASDAQ:UTHR)",
            "description": "B. Metzler seel. Sohn & Co. AG acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 908 shares of the biotechnology company\u2019s stock, valued at a\u2026",
            "url": "https://www.etfdailynews.com/2023/12/01/b-metzler-seel-sohn-co-ag-acquires-shares-of-908-united-therapeutics-co-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-12-01T15:02:44Z",
            "content": "B. Metzler seel. Sohn &amp; Co. AG acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acqui\u2026 [+7019 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Axiom Investors LLC DE Sells 227 Shares of United Therapeutics Co. (NASDAQ:UTHR)",
            "description": "Axiom Investors LLC DE trimmed its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 6.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,196 shares of the biotec\u2026",
            "url": "https://www.etfdailynews.com/2023/11/21/axiom-investors-llc-de-sells-227-shares-of-united-therapeutics-co-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-11-21T13:54:47Z",
            "content": "Axiom Investors LLC DE trimmed its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 6.6% during the second quarter, according to the company in its most recent Form 13F fi\u2026 [+6500 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Hsbc Holdings PLC Buys 21,995 Shares of United Therapeutics Co. (NASDAQ:UTHR)",
            "description": "Hsbc Holdings PLC increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 33.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87\u2026",
            "url": "https://www.etfdailynews.com/2023/11/29/hsbc-holdings-plc-buys-21995-shares-of-united-therapeutics-co-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-11-29T14:00:42Z",
            "content": "Hsbc Holdings PLC increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 33.5% during the 2nd quarter, according to the company in its most recent 13F filing with the\u2026 [+6951 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Sectoral Asset Management Inc. Has $496,000 Stock Position in United Therapeutics Co. (NASDAQ:UTHR)",
            "description": "Sectoral Asset Management Inc. grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 23.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,247 shares of t\u2026",
            "url": "https://www.etfdailynews.com/2023/11/28/sectoral-asset-management-inc-has-496000-stock-position-in-united-therapeutics-co-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-11-28T17:02:53Z",
            "content": "Sectoral Asset Management Inc. grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 23.8% during the 2nd quarter, according to its most recent 13F filing with the Securi\u2026 [+7240 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Mn Services Vermogensbeheer B.V. Takes Position in United Therapeutics Co. (NASDAQ:UTHR)",
            "description": "Mn Services Vermogensbeheer B.V. bought a new position in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) during the second quarter, Holdings Channel reports. The firm bought 22,100 shares of the biotechnology company\u2019s stock, valued at approximately $4,8\u2026",
            "url": "https://www.etfdailynews.com/2023/11/15/mn-services-vermogensbeheer-b-v-takes-position-in-united-therapeutics-co-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-11-15T11:30:46Z",
            "content": "Mn Services Vermogensbeheer B.V. bought a new position in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) during the second quarter, Holdings Channel reports. The firm bought 22,100 shares of the\u2026 [+6778 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "B. Metzler seel. Sohn & Co. AG Takes $200,000 Position in United Therapeutics Co. (NASDAQ:UTHR)",
            "description": "B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 908 sh\u2026",
            "url": "https://www.etfdailynews.com/2023/12/01/b-metzler-seel-sohn-co-ag-takes-200000-position-in-united-therapeutics-co-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-12-01T15:02:44Z",
            "content": "B. Metzler seel. Sohn &amp; Co. AG acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) during the second quarter, according to its most recent disclosure with the Se\u2026 [+6653 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Principal Financial Group Inc. Purchases 1,341 Shares of United Therapeutics Co. (NASDAQ:UTHR)",
            "description": "Principal Financial Group Inc. boosted its stake in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 0.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 181,672 shares\u2026",
            "url": "https://www.etfdailynews.com/2023/11/11/principal-financial-group-inc-purchases-1341-shares-of-united-therapeutics-co-nasdaquthr/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-therapeutics-co-logo.png?v=20221107152717&w=240&h=240&zc=2",
            "publishedAt": "2023-11-11T14:10:20Z",
            "content": "Principal Financial Group Inc. boosted its stake in United Therapeutics Co. (NASDAQ:UTHR \u2013 Free Report) by 0.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Sec\u2026 [+6832 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "SPHERICAL INSIGHTS LLP",
            "title": "Global Hemoglobinopathies Market Size To Worth USD 19.45 Billion By 2032 | CAGR of 9.5%",
            "description": "The Global Hemoglobinopathies Market Size was valued at USD 7.85 Billion in 2022 and the Worldwide Hemoglobinopathies Market Size is expected to reach USD 19.45 Billion by 2032, according to a research report published by Spherical Insights & Consulting. Comp\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/12/04/2789725/0/en/Global-Hemoglobinopathies-Market-Size-To-Worth-USD-19-45-Billion-By-2032-CAGR-of-9-5.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/b27a94e8-407e-46ae-a5c2-47bb2a1c8a2e",
            "publishedAt": "2023-12-04T08:00:00Z",
            "content": "New York, United States, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The Global Hemoglobinopathies Market Size is to Grow from USD 7.85 Billion in 2022 to USD 19.45 Billion by 2032, at a Compound Annual Growth\u2026 [+11286 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "MIROMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Miromatrix Medical Inc. - MIRO",
            "description": "(marketscreener.com) \nFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Miromatrix Medical Inc. to United Therapeutics Corporation . Under the terms of the propose\u2026",
            "url": "https://www.marketscreener.com/quote/stock/MIROMATRIX-MEDICAL-INC-124007895/news/MIROMATRIX-INVESTOR-ALERT-by-the-Former-Attorney-General-of-Louisiana-Kahn-Swick-Foti-LLC-Invest-45365214/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-15T21:33:01Z",
            "content": "Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (KSF) are investigating the proposed sale of Miromatrix Medical Inc. (NasdaqCM: MIRO) to\u2026 [+1224 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Ocular Hypertension Market Size and Share to Increase by 2032, Asserts DelveInsight | Leading Companies in the Market- Nicox, Glaukos, AbbVie, TearClear, Ocular, Perfuse",
            "description": "Several approved therapies such as EYBELIS, Durysta, Alphagan-P, Rhopressa, etc. will drive the current therapeutic landscape of ocular hypertension in the US, and the ocular hypertension market is estimated to increase by 2032. The primary reason for the ocu\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/22/2784994/0/en/Ocular-Hypertension-Market-Size-and-Share-to-Increase-by-2032-Asserts-DelveInsight-Leading-Companies-in-the-Market-Nicox-Glaukos-AbbVie-TearClear-Ocular-Perfuse.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-11-22T18:00:00Z",
            "content": "New York, USA, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Ocular Hypertension Market Size and Share to Increase by 2032, Asserts DelveInsight | Leading Companies in the Market- Nicox, Glaukos, AbbVie, TearCle\u2026 [+15587 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "PR Newswire UK"
            },
            "author": null,
            "title": "Vitiligo Market Growth to Undergo Significant Changes by 2032, Predicts DelveInsight | Key Companies in the Market - Clinuvel Pharmaceuticals Limited, Pfizer, Incyte Corporation, Amgen",
            "description": "The available therapeutics treatment options in the vitiligo market landscape aim to reduce complications arising. The dynamics of the vitiligo market are anticipated to change in the coming years owing to the improvement in the rise in number of healthcare s\u2026",
            "url": "https://www.prnewswire.co.uk/news-releases/vitiligo-market-growth-to-undergo-significant-changes-by-2032-predicts-delveinsight--key-companies-in-the-market---clinuvel-pharmaceuticals-limited-pfizer-incyte-corporation-amgen-301980757.html",
            "urlToImage": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
            "publishedAt": "2023-11-07T22:02:00Z",
            "content": "The available therapeutics treatment options in the vitiligo market landscape aim to reduce complications arising. The dynamics of the vitiligo market are anticipated to change in the coming years ow\u2026 [+11832 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Halper Sadeh LLC",
            "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BBAI, MIRO",
            "description": "NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:",
            "url": "https://www.globenewswire.com/news-release/2023/11/16/2781507/0/en/SHAREHOLDER-INVESTIGATION-Halper-Sadeh-LLC-Investigates-BBAI-MIRO.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/54cbaf70-16fe-4ac1-8956-c2d21ff8ae45",
            "publishedAt": "2023-11-16T02:14:00Z",
            "content": "NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or brea\u2026 [+1469 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Brodsky & Smith LLC",
            "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eargo, Inc. (Nasdaq \u2013 EAR), Miromatrix Medical, Inc. (Nasdaq \u2013 MIRO), Physicians Realty Trust (NYSE \u2013 DOC), Spirit Realty Capital (NYSE \u2013 SRC)",
            "description": "BALA CYNWYD, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brods\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/13/2779195/0/en/BRODSKY-SMITH-SHAREHOLDER-UPDATE-Notifying-Investors-of-the-Following-Investigations-Eargo-Inc-Nasdaq-EAR-Miromatrix-Medical-Inc-Nasdaq-MIRO-Physicians-Realty-Trust-NYSE-DOC-Spirit.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/aeea7200-7231-49dd-b4ba-ec680464b28c",
            "publishedAt": "2023-11-13T15:19:00Z",
            "content": "BALA CYNWYD, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Brodsky &amp; Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brods\u2026 [+3521 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research Nester",
            "title": "Peptide Synthesis Market revenue to reach USD 6 Billion by 2035, says Research Nester",
            "description": "Key peptide synthesis market players include Bachem Holding AG, Biotage, AAPP Tec, CEM Corporation ProteoGenix, GenScript, and Thermo Fisher Scientific Inc. Key peptide synthesis market players include Bachem Holding AG, Biotage, AAPP Tec, CEM Corporation Pro\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/20/2783048/0/en/Peptide-Synthesis-Market-revenue-to-reach-USD-6-Billion-by-2035-says-Research-Nester.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/77e335b1-e272-4a4c-a0ff-211ce0caee29",
            "publishedAt": "2023-11-20T11:00:00Z",
            "content": "New York , Nov. 20, 2023 (GLOBE NEWSWIRE) -- The global peptide synthesis market size is estimated to attain at 10% CAGR from 2023 to 2035. The market is expected to garner a revenue of USD 6 billion\u2026 [+10987 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, HES, SIX, MIRO",
            "description": "(marketscreener.com) \n\nNEW YORK, Nov. 30, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders \u2026",
            "url": "https://www.marketscreener.com/quote/stock/SIX-FLAGS-ENTERTAINMENT-C-5371870/news/SHAREHOLDER-INVESTIGATION-Halper-Sadeh-LLC-Investigates-MRTX-HES-SIX-MIRO-45475777/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-30T16:38:03Z",
            "content": "NEW YORK, Nov. 30, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches\u2026 [+2913 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ValueWalk"
            },
            "author": "Brendan Byrne",
            "title": "Safra Catz Net Worth: A Journey to Oracle\u2019s Top",
            "description": "Explore the financial world of Oracle's CEO, Safra Catz. Learn about her net worth, the building blocks of her wealth, and how she enjoys her fortunes. Click for details.",
            "url": "https://www.valuewalk.com/net-worth/safra-catz/",
            "urlToImage": "https://www.valuewalk.com/wp-content/uploads/2023/11/safra-catz-salary.jpg",
            "publishedAt": "2023-11-18T16:37:53Z",
            "content": "Safra Ada Catz is an Israeli-born American technology executive with a net worth of $1.7 billion. She has worked with Oracle Corporations since 1999 and now serves as the companys CEO. Safra joined O\u2026 [+8474 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MIRO, SRC, PATI, FIXX",
            "description": "(marketscreener.com) \n\nNEW YORK, Nov. 21, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders \u2026",
            "url": "https://www.marketscreener.com/quote/stock/SPIRIT-REALTY-CAPITAL-INC-49428550/news/SHAREHOLDER-INVESTIGATION-Halper-Sadeh-LLC-Investigates-MIRO-SRC-PATI-FIXX-45403528/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-21T07:03:03Z",
            "content": "NEW YORK, Nov. 21, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches\u2026 [+2567 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Halper Sadeh LLC",
            "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGH, CSTR, MIRO",
            "description": "NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:",
            "url": "https://www.globenewswire.com/news-release/2023/11/23/2785089/0/en/SHAREHOLDER-INVESTIGATION-Halper-Sadeh-LLC-Investigates-TGH-CSTR-MIRO.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/54cbaf70-16fe-4ac1-8956-c2d21ff8ae45",
            "publishedAt": "2023-11-23T00:19:00Z",
            "content": "NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or brea\u2026 [+1728 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSTR, MIRO, SRC",
            "description": "(marketscreener.com) \n\nNEW YORK, Nov. 7, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders r\u2026",
            "url": "https://www.marketscreener.com/quote/stock/SPIRIT-REALTY-CAPITAL-INC-49428550/news/SHAREHOLDER-INVESTIGATION-Halper-Sadeh-LLC-Investigates-CSTR-MIRO-SRC-45262077/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-07T15:40:04Z",
            "content": "NEW YORK, Nov. 7, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches \u2026 [+2313 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards",
            "description": "(marketscreener.com) LAUSANNE, Switzerland, Nov. 07, 2023 -- ADC Therapeutics SA today announced that on October 10, 2023, it received a notice from the New York Stock Exchange that the Company is not in compliance with the continued listing minimum price cri\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ADC-THERAPEUTICS-SA-66481721/news/ADC-Therapeutics-Receives-NYSE-Notice-of-Non-Compliance-With-Continued-Listing-Standards-45259429/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-07T12:16:02Z",
            "content": "LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that t\u2026 [+6597 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update",
            "description": "(marketscreener.com) Oral arguments in appeal of \u2018793 PTAB decision set for December 4, 2023PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024Hired sales force in preparation of potential positive legal and regulatory outcomes MORR\u2026",
            "url": "https://www.marketscreener.com/quote/stock/LIQUIDIA-CORPORATION-45064777/news/Liquidia-Corporation-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update-45258687/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-07T11:31:02Z",
            "content": "<ul><li>Oral arguments in appeal of 793 PTAB decision set for December 4, 2023</li><li>PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024</li><li>Hired sales force in prep\u2026 [+19562 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Postoperative Pain Market is Projected to Grow at a CAGR of 7.2% by 2032 | DelveInsight",
            "description": "The dynamics of the postoperative pain market are anticipated to change in the coming years owing to the emerging pipeline including drugs such as APP13007 (Formosa Pharmaceuticals), OCS-01 (Oculis), TLC590 (Taiwan Liposome Company), VX-548 (Vertex Pharmaceut\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/12/04/2790319/0/en/Postoperative-Pain-Market-is-Projected-to-Grow-at-a-CAGR-of-7-2-by-2032-DelveInsight.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-12-04T18:00:00Z",
            "content": "New York, USA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Postoperative Pain Market is Projected to Grow at a CAGR of 7.2% by 2032 | DelveInsight\u00a0\r\nThe dynamics of the postoperative pain market are anticipate\u2026 [+17274 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Major Depressive Disorder Market to Register Stunning Growth During the Forecast Period (2023\u20132032), Examines DelveInsight | Leading Companies - Otsuka, Sumitomo, COMPASS, Sage, Neurocrine, Boehringer Ingelheim, Janssen",
            "description": "The dynamics of the major depressive disorder market are anticipated to change in the coming years owing to the improvement in the research and development undertaking. In addition, persistently rising cases of MDD in the forecast period and the anticipated l\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/16/2782143/0/en/Major-Depressive-Disorder-Market-to-Register-Stunning-Growth-During-the-Forecast-Period-2023-2032-Examines-DelveInsight-Leading-Companies-Otsuka-Sumitomo-COMPASS-Sage-Neurocrine-Bo.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-11-16T18:00:00Z",
            "content": "New York, USA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Major Depressive Disorder Market to Register Stunning Growth During the Forecast Period (20232032), Examines DelveInsight | Leading Companies - Otsuka\u2026 [+15959 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Glaucoma Market to Accelerate Substantially During the Forecast Period (2023\u20132032), Examines DelveInsight | Leading Companies - Nicox, SPARC, Visiox, Glaukos, Ono, Santen, Ocular, Tarsier, Peregrine Ophthalmic, Ocuphire",
            "description": "The dynamics of the glaucoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emer\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/08/2776582/0/en/Glaucoma-Market-to-Accelerate-Substantially-During-the-Forecast-Period-2023-2032-Examines-DelveInsight-Leading-Companies-Nicox-SPARC-Visiox-Glaukos-Ono-Santen-Ocular-Tarsier-Peregr.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-11-08T18:00:00Z",
            "content": "New York, USA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Glaucoma Market to Accelerate Substantially During the Forecast Period (20232032), Examines DelveInsight | Leading Companies - Nicox, SPARC, Visiox, G\u2026 [+15637 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MIRO, EAR, DOC",
            "description": "(marketscreener.com) \n\nNEW YORK, Nov. 13, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders \u2026",
            "url": "https://www.marketscreener.com/quote/stock/PHYSICIANS-REALTY-TRUST-13659304/news/SHAREHOLDER-INVESTIGATION-Halper-Sadeh-LLC-Investigates-MIRO-EAR-DOC-45314772/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-13T19:11:04Z",
            "content": "NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches\u2026 [+2272 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "CURE Media Group",
            "title": "CURE Media Group\u00ae announces Jane Fonda as keynote speaker for the 2023 MPN Heroes\u00ae recognition program",
            "description": "CURE\u00a0and Incyte Corporation are proud to host the 2023 MPN Heroes\u00a0recognition ceremony, an evening of gratitude and celebration of the heroes who have made a significant impact in the lives of patients with myeloproliferative neoplasms, or MPNs.",
            "url": "https://www.globenewswire.com/news-release/2023/11/16/2782033/0/en/CURE-Media-Group-announces-Jane-Fonda-as-keynote-speaker-for-the-2023-MPN-Heroes-recognition-program.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/29d5e063-4d8e-44b8-a501-2d813cb0cbd4",
            "publishedAt": "2023-11-16T15:38:00Z",
            "content": "CURE\u00a0and Incyte Corporation are proud to host the 2023 MPN Heroes\u00a0recognition ceremony, an evening of gratitude and celebration of the heroes who have made a significant impact in the lives of patien\u2026 [+4069 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Intratumoral Cancer Therapies Market to Observe Stupendous Growth During the Forecast Period (2023\u20132032), Assesses DelveInsight | Key Players - Nanobiotix, Sirnaomics, Apexigen, Replimune, Merck, OncoSec, DNAtrix, Treovir Istari",
            "description": "The dynamics of the intratumoral cancer therapies market are anticipated to change in the coming years owing to the approval of several drugs targeting different cancer indications. The dynamics of the intratumoral cancer therapies market are anticipated to c\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/15/2781338/0/en/Intratumoral-Cancer-Therapies-Market-to-Observe-Stupendous-Growth-During-the-Forecast-Period-2023-2032-Assesses-DelveInsight-Key-Players-Nanobiotix-Sirnaomics-Apexigen-Replimune-Me.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-11-15T18:00:00Z",
            "content": "New York, USA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intratumoral Cancer Therapies Market to Observe Stupendous Growth During the Forecast Period (20232032), Assesses DelveInsight | Key Players - Nanobio\u2026 [+17102 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "United States Wound Biologics Market Insights 2023-2028: with Avita Medical, Organogenesis, Smith+Nephew, Vericel, and Orthofix Dominating",
            "description": "Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The \"US Wound Biologics Market - Focused Insights 2023-2028\" report has been added to ResearchAndMarkets.com's offering.",
            "url": "https://www.globenewswire.com/news-release/2023/11/22/2784893/28124/en/United-States-Wound-Biologics-Market-Insights-2023-2028-with-Avita-Medical-Organogenesis-Smith-Nephew-Vericel-and-Orthofix-Dominating.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-11-22T15:18:00Z",
            "content": "Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The \"US Wound Biologics Market - Focused Insights 2023-2028\" report has been added to ResearchAndMarkets.com's offering.\r\nUS wound biologics market was value\u2026 [+4539 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer",
            "description": "(marketscreener.com) \n\nHONG KONG,\u00a0Germantown, Md. and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. , a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the promotion of Dr. F\u2026",
            "url": "https://www.marketscreener.com/quote/stock/SIRNAOMICS-LTD-131014685/news/Sirnaomics-Promotes-Francois-Lebel-M-D-to-Chief-Medical-Officer-45479605/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-12-01T06:36:03Z",
            "content": "HONG KONG,\u00a0Germantown, Md. and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the \"Company\"; stock code: 2257, together with its subsidiaries, the \"Group\" or \"Sirnaomics\"), a leading bi\u2026 [+3884 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "InvestorsObserver"
            },
            "author": "InvestorsObserver",
            "title": "Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer",
            "description": "Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer           PR Newswire           HONG KONG,&#xA0;Germantown, Md. and Suzhou,   China     ,     Dec. 1, 2023     /PRNewswire/ --   Sirnaomics Ltd.   (the \"Company\"; stock code: 2257, toget...",
            "url": "https://www.investorsobserver.com/news/qm-pr/8280678081500217",
            "urlToImage": "https://s3.amazonaws.com/images.investorsobserver.com/io-logo-800x450.jpg",
            "publishedAt": "2023-12-01T01:35:00Z",
            "content": "HONG KONG,\u00a0Germantown, Md. and Suzhou,\r\nChina\r\n,\r\nDec. 1, 2023\r\n/PRNewswire/ --\r\nSirnaomics Ltd.\r\n(the \"Company\"; stock code: 2257, together with its subsidiaries, the \"Group\" or \"Sirnaomics\"), a lea\u2026 [+3925 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Smoking Cessation Market to Grow at a Substantial Growth Rate During the Forecast Period (2023\u20132032), Assesses DelveInsight | Key Companies - Axsome Therapeutics, Achieve Life Sciences, Chronic Airway Therapeutics, Smoke Free Therapeutics",
            "description": "The increase in the smoking cessation market size is a direct consequence of the expected approval of emerging therapies and the increasingly diagnosed prevalent population of smoking cessation in the 7MM. The increase in the smoking cessation market size is \u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/30/2788858/0/en/Smoking-Cessation-Market-to-Grow-at-a-Substantial-Growth-Rate-During-the-Forecast-Period-2023-2032-Assesses-DelveInsight-Key-Companies-Axsome-Therapeutics-Achieve-Life-Sciences-Chr.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-11-30T18:00:00Z",
            "content": "New York, USA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Smoking Cessation Market to Grow at a Substantial Growth Rate During the Forecast Period (20232032), Assesses DelveInsight | Key Companies - Axsome Th\u2026 [+13171 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "ADC Therapeutics SA",
            "title": "ADC Therapeutics to Participate in the Jefferies London Healthcare Conference",
            "description": "LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 14th a\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/06/2773904/0/en/ADC-Therapeutics-to-Participate-in-the-Jefferies-London-Healthcare-Conference.html",
            "urlToImage": "https://ml-eu.globenewswire.com/Resource/Download/42234478-810e-48c2-aadd-36edac51810d",
            "publishedAt": "2023-11-06T12:00:00Z",
            "content": "LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jeffer\u2026 [+5530 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Kynexis",
            "title": "Kynexis Launched to Advance Precision Therapeutics for Brain Diseases",
            "description": "- Lead Candidate KYN-5356, a First-In-Class Small Molecule KAT-II Inhibitor, Advancing Toward the Clinic for Cognitive Impairment Associated With Schizophrenia",
            "url": "https://www.globenewswire.com/news-release/2023/11/07/2774771/0/en/Kynexis-Launched-to-Advance-Precision-Therapeutics-for-Brain-Diseases.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/cc6eebb7-91d8-415e-8e68-54f1c4bf5ef4",
            "publishedAt": "2023-11-07T10:00:00Z",
            "content": "- Lead Candidate KYN-5356, a First-In-Class Small Molecule KAT-II Inhibitor, Advancing Toward the Clinic for Cognitive Impairment Associated With Schizophrenia\r\n- 57 Million Series A Led by Forbion\r\n\u2026 [+5637 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Moore Kuehn",
            "title": "Moore Kuehn Encourages BBAI, SIX, MIRO, and BVH Investors to Contact Law Firm",
            "description": "NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to share\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/09/2777542/0/en/Moore-Kuehn-Encourages-BBAI-SIX-MIRO-and-BVH-Investors-to-Contact-Law-Firm.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/fcd51639-a5fc-4083-b724-b8817587c557",
            "publishedAt": "2023-11-09T15:17:00Z",
            "content": "NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concern\u2026 [+2434 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Liquidia Corporation",
            "title": "Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update",
            "description": "MORRISVILLE, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the third quarter ended September 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the \u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/07/2774862/0/en/Liquidia-Corporation-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/cb5aca76-917e-4e82-a174-9086b747a4ce",
            "publishedAt": "2023-11-07T11:30:00Z",
            "content": "<ul><li>Oral arguments in appeal of 793 PTAB decision set for December 4, 2023</li><li>PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024</li><li>Hired sales force in prep\u2026 [+19553 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Halper Sadeh LLC",
            "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SRC, PATI, FIXX, FRLN",
            "description": "NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:",
            "url": "https://www.globenewswire.com/news-release/2023/11/23/2785084/0/en/SHAREHOLDER-INVESTIGATION-Halper-Sadeh-LLC-Investigates-SRC-PATI-FIXX-FRLN.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/54cbaf70-16fe-4ac1-8956-c2d21ff8ae45",
            "publishedAt": "2023-11-23T00:10:00Z",
            "content": "NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or brea\u2026 [+1872 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Moore Kuehn Encourages SRC, MIRO, DOC, and SIX Investors to Contact Law Firm",
            "description": "(marketscreener.com) \n\nNEW YORK, Nov. 7, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers\u2026",
            "url": "https://www.marketscreener.com/quote/stock/SPIRIT-REALTY-CAPITAL-INC-49428550/news/Moore-Kuehn-Encourages-SRC-MIRO-DOC-and-SIX-Investors-to-Contact-Law-Firm-45263564/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-07T18:53:03Z",
            "content": "NEW YORK, Nov. 7, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning w\u2026 [+2591 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "ADC Therapeutics SA",
            "title": "ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards",
            "description": "LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with the continued listing m\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/07/2774952/0/en/ADC-Therapeutics-Receives-NYSE-Notice-of-Non-Compliance-With-Continued-Listing-Standards.html",
            "urlToImage": "https://ml-eu.globenewswire.com/Resource/Download/42234478-810e-48c2-aadd-36edac51810d",
            "publishedAt": "2023-11-07T12:15:00Z",
            "content": "LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that t\u2026 [+6590 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Brian Bushard, Forbes Staff, \n Brian Bushard, Forbes Staff\n https://www.forbes.com/sites/brianbushard/",
            "title": "2023 Layoff Tracker: Pfizer Cuts 781 Employees",
            "description": "Hundreds of U.S. companies have slashed their workforces this year, including Amazon, Google, Meta and Disney.",
            "url": "https://www.forbes.com/sites/brianbushard/2023/11/07/2023-layoff-tracker-pfizer-cuts-781-employees/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/654a536c84440b20edd0114c/0x0.jpg?format=jpg&crop=3000,1689,x0,y146,safe&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-11-07T15:23:25Z",
            "content": "Pfizer will lay off 781 employees from a facility in New Jersey, according to a state filing, as the drugmakers financial woes continue amid waning demand for Covid-19 vaccines and as lingering reces\u2026 [+33952 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Brian Bushard, Forbes Staff, \n Brian Bushard, Forbes Staff\n https://www.forbes.com/sites/brianbushard/",
            "title": "2023 Layoff Tracker: Advance Auto Parts Cuts 400 Employees",
            "description": "Hundreds of U.S. companies have slashed their workforces this year, including Amazon, Google, Meta and Disney.",
            "url": "https://www.forbes.com/sites/brianbushard/2023/11/16/2023-layoff-tracker-advance-auto-parts-cuts-400-employees/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/655657464fc97f7dec18dd58/0x0.jpg?format=jpg&crop=1895,1066,x0,y0,safe&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-11-16T18:06:21Z",
            "content": "National auto parts chain Advance Auto Parts announced plans this week to cut roughly 400 employees, as lingering recession fears prompt large companies to cut costs (see Forbes layoff tracker from t\u2026 [+35655 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Brian Bushard, Forbes Staff, \n Brian Bushard, Forbes Staff\n https://www.forbes.com/sites/brianbushard/",
            "title": "2023 Layoff Tracker: Amazon Cutting 180 Gaming Employees",
            "description": "Hundreds of U.S. companies have slashed their workforces this year, including Amazon, Google, Meta and Disney.",
            "url": "https://www.forbes.com/sites/brianbushard/2023/11/13/2023-layoff-tracker-amazon-cutting-180-gaming-employees/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/65526f7af69b4d135b7dac78/0x0.jpg?format=jpg&crop=3403,1912,x0,y0,safe&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-11-13T18:51:44Z",
            "content": "Amazon plans to lay off more than 180 employees in its games division as part of a restructuring, as lingering recession fears prompt large companies to cut costs (see Forbes layoff tracker from the \u2026 [+34986 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Tenax Therapeutics",
            "title": "Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board",
            "description": "CHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/17/2782563/0/en/Tenax-Therapeutics-Announces-Professor-Javed-Butler-M-D-M-P-H-M-B-A-joins-PH-HFpEF-Scientific-Advisory-Board.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/300a2ad0-1890-41f1-89c8-2ee56b64bb13",
            "publishedAt": "2023-11-17T13:30:00Z",
            "content": "CHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that a\u2026 [+9868 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Brian Bushard, Forbes Staff, \n Brian Bushard, Forbes Staff\n https://www.forbes.com/sites/brianbushard/",
            "title": "2023 Layoff Tracker: Dish Network Cuts 500 Employees",
            "description": "Hundreds of U.S. companies have slashed their workforces this year, including Amazon, Google, Meta and Disney.",
            "url": "https://www.forbes.com/sites/brianbushard/2023/11/09/2023-layoff-tracker-dish-network-cuts-500-employees/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/654cfdc84800727b56382ab2/0x0.jpg?format=jpg&crop=4158,2340,x0,y143,safe&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-11-09T15:55:28Z",
            "content": "Dish Network plans to lay off more than 500 employees, multiple outlets reported this week, as part of a major cost reduction plan at the satellite TV provider, and as lingering recession fears promp\u2026 [+34754 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Brian Bushard, Forbes Staff, \n Brian Bushard, Forbes Staff\n https://www.forbes.com/sites/brianbushard/",
            "title": "2023 Layoff Tracker: Chewy Cuts 200 Employees, Report Says",
            "description": "Hundreds of U.S. companies have slashed their workforces this year, including Amazon, Google, Meta and Disney.",
            "url": "https://www.forbes.com/sites/brianbushard/2023/11/15/2023-layoff-tracker-chewy-cuts-200-employees-report-says/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/6554e17dc2110fe8053270a1/0x0.jpg?format=jpg&crop=1788,1006,x0,y89,safe&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-11-15T15:25:19Z",
            "content": "Online pet supply company Chewy plans to lay off roughly 200 employees, the Florida-based company confirmed to TechCrunch, as lingering recession fears prompt large companies to cut costs (see Forbes\u2026 [+35361 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Brian Bushard, Forbes Staff, \n Brian Bushard, Forbes Staff\n https://www.forbes.com/sites/brianbushard/",
            "title": "2023 Layoff Tracker: Nextdoor Cuts 176 Employees",
            "description": "Hundreds of U.S. companies have slashed their workforces this year, including Amazon, Google, Meta and Disney.",
            "url": "https://www.forbes.com/sites/brianbushard/2023/11/08/2023-layoff-tracker-nextdoor-cuts-176-employees/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/654a536c84440b20edd0114c/0x0.jpg?format=jpg&crop=3000,1689,x0,y146,safe&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-11-08T15:24:29Z",
            "content": "Neighborhood-centered social media company Nextdoor plans to cut 25% of its workforce as part of a major cost reduction plan, as lingering recession fears prompt large companies to cut costs (see For\u2026 [+34306 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "PR Newswire UK"
            },
            "author": null,
            "title": "Herpes Zoster Market Size and Share to Grow Positively by 2032, Assesses DelveInsight | Leading Companies - Immorna, ICON, Curevo, Green Cross Corporation, ModernaTX, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb",
            "description": "The dynamics of the herpes zoster market are anticipated to change during the forecast period (2023\u20132032) owing to emerging therapies expected launch, rising incidence of herpes zoster, and increasing awareness and high demand for shingles prevention. LAS VEG\u2026",
            "url": "https://www.prnewswire.co.uk/news-releases/herpes-zoster-market-size-and-share-to-grow-positively-by-2032-assesses-delveinsight--leading-companies---immorna-icon-curevo-green-cross-corporation-modernatx-pfizer-glaxosmithkline-bristol-myers-squibb-301981163.html",
            "urlToImage": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
            "publishedAt": "2023-11-08T22:01:00Z",
            "content": "The dynamics of the herpes zoster market are anticipated to change during the forecast period (20232032) owing to emerging therapies expected launch, rising incidence of herpes zoster, and increasing\u2026 [+12521 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates",
            "description": "(marketscreener.com) \n\u2013 STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat dosing on seizure frequency, cognition, and behavior from the ongoing open-label extension studies \u2013\n\n\n\u2013 STK-001\u2026",
            "url": "https://www.marketscreener.com/quote/stock/STOKE-THERAPEUTICS-INC-60037730/news/Stoke-Therapeutics-Reports-Third-Quarter-Financial-Results-and-Provides-Business-Updates-45259280/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-07T12:06:01Z",
            "content": "STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat dosing on seizure frequency, cognition, and behavior from the ongoing open-l\u2026 [+26944 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "InvestorsObserver"
            },
            "author": "InvestorsObserver",
            "title": "Novo Integrated Sciences' Purchase and Sale Agreement to Acquire Ophir Collection Receives Court Approval",
            "description": "Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the &#x201C;Company&#x201D; or &#x201C;Novo&#x201D;) today announced the United States District Court for the Central District of California has approved the Purchase and Sale Agreement (&#x201C;PSA&#x201D...",
            "url": "https://www.investorsobserver.com/news/qm-pr/6812111481540177",
            "urlToImage": "https://s3.amazonaws.com/images.investorsobserver.com/io-logo-800x450.jpg",
            "publishedAt": "2023-12-04T11:30:00Z",
            "content": "News HomeMentioned in this article\r\nNovo Integrated Sciences, Inc. (NASDAQ: NVOS) (the \u201cCompany\u201d or \u201cNovo\u201d) today announced the United States District Court for the Central District of California has\u2026 [+6230 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals, Inc., Tenaya Therapeutics, Novartis",
            "description": "The hypertrophic cardiomyopathy market dynamics are anticipated to change during the forecast period (2023\u20132032) due to the expected launch of emerging therapies. The hypertrophic cardiomyopathy market dynamics are anticipated to change during the forecast pe\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/14/2780408/0/en/Hypertrophic-Cardiomyopathy-Treatment-Market-to-Exhibit-Impressive-Growth-by-2023-Predicts-DelveInsight-Key-Companies-Cytokinetics-Bristol-Myers-Squibb-Imbria-Pharmaceuticals-Inc-T.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-11-14T18:00:00Z",
            "content": "New York, USA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics, Bristol-Myers\u2026 [+14422 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Thefly.com"
            },
            "author": null,
            "title": "What You Missed On Wall Street This Morning",
            "description": "See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor\u2026",
            "url": "https://thefly.com/permalinks/entry.php/id3824986/GM;LULU;HA;ALK;UBER;RHHBY;VZ;NFLX;WBD;TWLO;SPOT;FSR;FLNC;CYBR;GETY;TSLA;SPCE;UBS;WMT;WBX;CVNA;RIOT;VFS;GERN;SAIC;CI;CHWY;GME;CHPT-What-You-Missed-On-Wall-Street-This-Morning",
            "urlToImage": "https://image.thefly.com/catalog/201810/img_66.png",
            "publishedAt": "2023-12-04T16:57:47Z",
            "content": "Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. \r\n1. STOCK NEWS: \r\n<ul><li>Alaska Airlines (ALK) agreed to acquire Hawaiian Airlines (HA) in a $1.9B deal\u2026 [+2067 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "TCR-Therapy Pipeline Research Report 2023: Comprehensive Insights on 30+ Companies and 100+ Pipeline Drugs",
            "description": "Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The \"TCR-Therapy - Pipeline Insight, 2023\" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 30+ companies and 100+ pipeline drugs in TCR-Therapy pipe\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/22/2784814/28124/en/TCR-Therapy-Pipeline-Research-Report-2023-Comprehensive-Insights-on-30-Companies-and-100-Pipeline-Drugs.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2023-11-22T13:48:00Z",
            "content": "Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The \"TCR-Therapy - Pipeline Insight, 2023\" drug pipelines has been added to ResearchAndMarkets.com's offering.\r\nThis report provides comprehensive insights a\u2026 [+9147 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K",
            "description": "(marketscreener.com) \n \n \n Voting ahead of attending the Meeting\n \n \n \n \n \n \n Shareholders are strongly encouraged to vote by lodging a directed proxy appointing the Chairman before 10:00 am Wednesday 27 December 2023. Instructions for lodging proxies are inc\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ALTERITY-THERAPEUTICS-LIM-57291688/news/Alterity-Therapeutics-Voting-ahead-of-attending-the-Meeting-Form-6-K-45472102/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-30T11:06:22Z",
            "content": "<table><tr><td>\r\n Voting ahead of attending the Meeting\r\n </td></tr></table><table><tr><td>\r\nShareholders are strongly encouraged to vote by lodging a directed proxy appointing the Chairman before 10\u2026 [+67198 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Phlow Corp.",
            "title": "Phlow Announces the Appointment of Kerry Ingalls and Guy Villax to its Board of Directors.",
            "description": "Richmond, Virginia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Phlow Corp., a Public Benefit pharmaceutical manufacturer, announced today the appointment of Kerry Ingalls and Guy Villax to its Board of Directors amid a period of rapid growth and operational scale-up o\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/27/2786357/0/en/Phlow-Announces-the-Appointment-of-Kerry-Ingalls-and-Guy-Villax-to-its-Board-of-Directors.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/f8ce3256-7d2e-4fed-91b1-91967305636e",
            "publishedAt": "2023-11-27T16:04:00Z",
            "content": "Richmond, Virginia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Phlow Corp., a Public Benefit pharmaceutical manufacturer, announced today the appointment of Kerry Ingalls and Guy Villax to its Board of Direct\u2026 [+3757 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "InsightAce Analytic Pvt. LTd.",
            "title": "mRNA Extraction and Purification Market Latest Q4 2023 Updated Report with Forecast to 2031",
            "description": "Companies covered in this report are Qiagen, Thermo Fisher Scientific, Promega Corporation, Agilent Technologies, Inc, Merck Kgaa, Miltenyi Biotec , Biobasic Inc, Takara Bio, Inc, New England Biolabs, Omega Bio-Tek, Inc, Norgen Biotek, Zymo Research, F. Hoffm\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/15/2780722/0/en/mRNA-Extraction-and-Purification-Market-Latest-Q4-2023-Updated-Report-with-Forecast-to-2031.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/0e88e2e9-67b2-4a38-aa13-e33c9d874fc5",
            "publishedAt": "2023-11-15T07:03:00Z",
            "content": "Jersey City, NJ, Nov. 15, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled \"Global mRNA Extraction and Purification Market\r\n- By\u2026 [+8708 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "SPHERICAL INSIGHTS LLP",
            "title": "Global Drug Discovery Services Market Size To Worth USD 61.32 Billion By 2032 | CAGR of 14.1%",
            "description": "The Global Drug Discovery Services Market Size was valued at USD 16.44 Billion in 2022 and the Worldwide Drug Discovery Services Market Size is expected to reach USD 61.32 Billion by 2032, according to a research report published by Spherical Insights & Consu\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/16/2781652/0/en/Global-Drug-Discovery-Services-Market-Size-To-Worth-USD-61-32-Billion-By-2032-CAGR-of-14-1.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/b27a94e8-407e-46ae-a5c2-47bb2a1c8a2e",
            "publishedAt": "2023-11-16T11:00:00Z",
            "content": "New York, United States, Nov. 16, 2023 (GLOBE NEWSWIRE) -- The Global Drug Discovery Services Market Size is to grow from USD 16.44 Billion in 2022 to USD 61.32 Billion by 2032, at a Compound Annual \u2026 [+10354 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Future Market Insights Global and Consulting Pvt. Ltd.",
            "title": "Central Lab Market is anticipated to reach around US$ 4,473.5 million by 2033, representing 5.8% growth through 2033 | Future Market Insights, Inc.",
            "description": "Global Central Lab Market Value to Expand by 2X over the Next Ten Years. Advancements in Healthcare Central Lab Sector to Drive the Market at 5.8% CAGR until 2033. United States leads global clinical testing central labs. 2022 revenue hits US$ 1,010.2 million\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/12/04/2789918/0/en/Central-Lab-Market-is-anticipated-to-reach-around-US-4-473-5-million-by-2033-representing-5-8-growth-through-2033-Future-Market-Insights-Inc.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/915d2f9c-7dc6-40c7-995c-2ba168208baa",
            "publishedAt": "2023-12-04T12:30:00Z",
            "content": "NEWARK, Del, Dec. 04, 2023 (GLOBE NEWSWIRE) -- In 2022, the net global central lab market size was roughly US$ 2,422.7 million. The global Central Lab industry is anticipated to increase at a 5.8% CA\u2026 [+7543 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "New York Post"
            },
            "author": "Josh Christenson",
            "title": "Brother of top White House aide makes $8M with boost from Biden agenda",
            "description": "The lobbyist brother of a senior White House aide has raked in more than $8 million from clients since President Biden took office in January 2021 \u2014 with several companies who retain the tied-in firm receiving direct boosts from the administration\u2019s legislati\u2026",
            "url": "https://nypost.com/2023/11/09/news/lobbyist-brother-of-white-house-senior-aide-raked-in-8-million-with-boosts-from-biden-agenda/",
            "urlToImage": "https://nypost.com/wp-content/uploads/sites/2/2023/11/NYPICHPDPICT000072072981.jpg?quality=75&strip=all&w=1024",
            "publishedAt": "2023-11-09T23:53:07Z",
            "content": "The lobbyist brother of a senior White House aide has raked in more than $8 million from clients since President Biden took office in January 2021 with several companies who retain the tied-in firm r\u2026 [+4831 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Tendinopathy Market to Register Incremental Growth During the Study Period (2019\u20132032), Estimates DelveInsight | Leading Companies in the Market - Novartis, SynOx, Abbisko, AmMax, Deciphera",
            "description": "The incidence of tendinopathy has been rising in recent years, and common explanations are the increasing age of society and the overall rise in extreme and overuse sports. There have been significant advancements in the field of tendinopathy market. Various \u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/29/2788013/0/en/Tendinopathy-Market-to-Register-Incremental-Growth-During-the-Study-Period-2019-2032-Estimates-DelveInsight-Leading-Companies-in-the-Market-Novartis-SynOx-Abbisko-AmMax-Deciphera.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-11-29T18:00:00Z",
            "content": "New York, USA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Tendinopathy Market to Register Incremental Growth During the Study Period (20192032), Estimates DelveInsight | Leading Companies in the Market -\u00a0 Nov\u2026 [+13041 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Vantage Market Research",
            "title": "Global Neuromodulation Market Size & Share to Surpass $14.8 Billion by 2030 | Vantage Market Research",
            "description": "WASHINGTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- According to Vantage Market Research, the Global Neuromodulation Market is estimated to be valued at USD 14.8 Billion by 2030 at an exponential growth of 12.2% in the next seven years.",
            "url": "https://www.globenewswire.com/news-release/2023/11/22/2784936/0/en/Global-Neuromodulation-Market-Size-Share-to-Surpass-14-8-Billion-by-2030-Vantage-Market-Research.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/b992ad70-52a5-4308-9ec3-ec32ebfecaee",
            "publishedAt": "2023-11-22T16:15:00Z",
            "content": "WASHINGTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- According to Vantage Market Research, the Global Neuromodulation Market is estimated to be valued at USD 14.8 Billion by 2030 at an exponential growth of\u2026 [+12165 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "JPMorgan Chase & Co. Reiterates \u201cUnderweight\u201d Rating for Amarin (NASDAQ:AMRN)",
            "description": "Amarin (NASDAQ:AMRN \u2013 Get Free Report)\u2018s stock had its \u201cunderweight\u201d rating reissued by investment analysts at JPMorgan Chase & Co. in a research note issued on Monday, Benzinga reports. Other research analysts have also recently issued research reports about\u2026",
            "url": "https://www.etfdailynews.com/2023/11/20/jpmorgan-chase-co-reiterates-underweight-rating-for-amarin-nasdaqamrn/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/amarin-co-plc-logo.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-20T14:24:41Z",
            "content": "Amarin (NASDAQ:AMRN \u2013 Get Free Report)\u2018s stock had its \u201cunderweight\u201d rating reissued by investment analysts at JPMorgan Chase &amp; Co. in a research note issued on Monday, Benzinga reports.\r\nOther r\u2026 [+3077 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "LCM Capital Management Inc Acquires 15,000 Shares of Amarin Co. plc (NASDAQ:AMRN)",
            "description": "LCM Capital Management Inc boosted its position in Amarin Co. plc (NASDAQ:AMRN \u2013 Free Report) by 4.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 346,159 shares of the\u2026",
            "url": "https://www.etfdailynews.com/2023/11/23/lcm-capital-management-inc-acquires-15000-shares-of-amarin-co-plc-nasdaqamrn/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/amarin-co-plc-logo.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-23T16:56:51Z",
            "content": "LCM Capital Management Inc boosted its position in Amarin Co. plc (NASDAQ:AMRN \u2013 Free Report) by 4.5% during the second quarter, according to the company in its most recent filing with the Securities\u2026 [+3716 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Oncotelic Therapeutics, Inc.",
            "title": "Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results",
            "description": "AGOURA HILLS, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (\"Oncotelic\", the \"Company\" or \"We\"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today a\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/15/2781074/0/en/Oncotelic-Reports-Q3-2023-Compared-to-Q3-2022-Financial-Results.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/f33cb86f-a73b-4a81-9274-bbef4c4172df",
            "publishedAt": "2023-11-15T14:00:00Z",
            "content": "<ul><li>R&amp;D cost remains essentially unchanged, while continuing expansion of our OT-101 clinical programs through our joint venture (JV)</li><li>G&amp;A cost significantly lower by over approxim\u2026 [+13340 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "PDS Biotechnology Corporation",
            "title": "PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results",
            "description": "PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccin\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/07/2775014/37149/en/PDS-Biotechnology-Announces-Conference-Call-and-Webcast-for-Third-Quarter-2023-Financial-Results.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/e2e7d124-dbd4-4140-9cc5-449d3488a902",
            "publishedAt": "2023-11-07T13:00:00Z",
            "content": "PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of t\u2026 [+7031 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "PDS Biotechnology Corporation",
            "title": "PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer",
            "description": "PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS Biotech\u201d or the \u201cCompany\u201d), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease va\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/28/2786835/37149/en/PDS-Biotech-Appoints-Lars-Boesgaard-as-Chief-Financial-Officer.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/e2e7d124-dbd4-4140-9cc5-449d3488a902",
            "publishedAt": "2023-11-28T12:30:00Z",
            "content": "PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of t\u2026 [+8826 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "FUJIFILM Holdings America Corporation",
            "title": "FUJIFILM Diosynth Biotechnologies Celebrates Site Unveiling for North Carolina Large-Scale Cell Culture Manufacturing Facility",
            "description": "Construction is on Schedule for Facility Poised to be Largest Cell Culture Biopharmaceutical CDMO Facility in North America Construction is on Schedule for Facility Poised to be Largest Cell Culture Biopharmaceutical CDMO Facility in North America",
            "url": "https://www.globenewswire.com/news-release/2023/11/07/2775490/0/en/FUJIFILM-Diosynth-Biotechnologies-Celebrates-Site-Unveiling-for-North-Carolina-Large-Scale-Cell-Culture-Manufacturing-Facility.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/3b04b160-9b69-48c4-be73-f8be26255051",
            "publishedAt": "2023-11-07T20:27:00Z",
            "content": "HOLLY SPRINGS, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advan\u2026 [+5698 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "SWK Holdings Corporation Announces Financial Results for Third Quarter 2023",
            "description": "(marketscreener.com) \n\nConference Call and Live Audio Webcast Scheduled for Thursday, November\u00a09, 2023, at 10:00 a.m. ET\nCorporate Highlights\nThird quarter of 2023 GAAP net income was $4.5 million or $0.36 per diluted share, compared with GAAP net income of $\u2026",
            "url": "https://www.marketscreener.com/quote/stock/SWK-HOLDINGS-CORPORATION-24260503/news/SWK-Holdings-Corporation-Announces-Financial-Results-for-Third-Quarter-2023-45285922/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-09T12:31:10Z",
            "content": "Conference Call and Live Audio Webcast Scheduled for Thursday, November\u00a09, 2023, at 10:00 a.m. ET\r\nCorporate Highlights\r\n<ul><li>Third quarter of 2023 GAAP net income was $4.5 million or $0.36 per di\u2026 [+38768 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Straits Research",
            "title": "Global Stem Cells Market to surge at a CAGR of 11.6%, targeting an estimated value of USD 31,950 Million by 2030 as per Straits Research",
            "description": "The stem cell industry is expected to grow considerably over the forecast period due to increased healthcare expenditure in developed countries and improvisation in healthcare facilities in developing countries. The stem cell industry is expected to grow cons\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/30/2788761/0/en/Global-Stem-Cells-Market-to-surge-at-a-CAGR-of-11-6-targeting-an-estimated-value-of-USD-31-950-Million-by-2030-as-per-Straits-Research.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/c25b8e5a-9a9f-499a-8eb6-76ff0d860959",
            "publishedAt": "2023-11-30T15:35:00Z",
            "content": "New York, United States, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Recent advancements in stem cell therapies and tissue engineering have the potential to attract interest in the treatment of a variety of ai\u2026 [+6815 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "EnGene Appoints Ryan Daws as Chief Financial Officer",
            "description": "(marketscreener.com) a disease with a high clinical burden. EG-70 is being evaluated in an ongoing Phase 2 pivotal study. EG-70 was developed using enGene's proprietary Dually Derivatized Oligochitosan platform, which enables penetration of mucosal tissues an\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ENGENE-HOLDINGS-INC-161300217/news/EnGene-Appoints-Ryan-Daws-as-Chief-Financial-Officer-45461199/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-29T12:01:08Z",
            "content": "BOSTON and MONTREAL, Nov. 29, 2023 /PRNewswire/ - enGene Holdings Inc. (\"enGene,\") (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study \u2026 [+7052 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "PR Newswire UK"
            },
            "author": null,
            "title": "Unraveling the Shifting Rare Eye Diseases Market Landscape: Analysis of Retinoblastoma Market, Retinitis Pigmentosa Market, Limbal Stem Cell Deficiency Market, Leber Hereditary Optic Neuropathy Market, and Stargardt Disease Market | DelveInsight",
            "description": "Several rare eye conditions are genetically influenced, which complicates the quest for effective treatments. Despite affecting only a small portion of the population, these rare eye diseases can have a profound impact on those affected. The paucity of precis\u2026",
            "url": "https://www.prnewswire.co.uk/news-releases/unraveling-the-shifting-rare-eye-diseases-market-landscape-analysis-of-retinoblastoma-market-retinitis-pigmentosa-market-limbal-stem-cell-deficiency-market-leber-hereditary-optic-neuropathy-market-and-stargardt-disease-market-301991315.html",
            "urlToImage": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
            "publishedAt": "2023-11-16T22:01:00Z",
            "content": "Several rare eye conditions are genetically influenced, which complicates the quest for effective treatments. Despite affecting only a small portion of the population, these rare eye diseases can hav\u2026 [+17210 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "SPHERICAL INSIGHTS LLP",
            "title": "Global Image-Guided Radiation Therapy Market Size To Worth USD 2.93 Billion by 2032 | CAGR of 5.1%",
            "description": "The Global Image-Guided Radiation Therapy Market Size was valued at USD 1.78 Billion in 2022 and the Worldwide Image-Guided Radiation Therapy Market Size is expected to reach USD 2.93 Billion by 2032, according to a research report published by Spherical Insi\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/30/2788356/0/en/Global-Image-Guided-Radiation-Therapy-Market-Size-To-Worth-USD-2-93-Billion-by-2032-CAGR-of-5-1.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/b27a94e8-407e-46ae-a5c2-47bb2a1c8a2e",
            "publishedAt": "2023-11-30T10:00:00Z",
            "content": "New York, United States, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The Global Image-Guided Radiation Therapy Market Size is to Grow from USD 1.78 Billion in 2022 to USD 2.93 Billion by 2032, at a Compound An\u2026 [+10094 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Olive Resource Capital Announces October 31, 2023 NAV of C$0.065 per Share",
            "description": "(marketscreener.com) Olive Resource Capital Inc. is pleased to provide investors an updated, unaudited Net Asset Value per share. Management has estimated the NAV of the Company at C$0.065 per share for October 31, 2023 . At the end of October, the Company's \u2026",
            "url": "https://www.marketscreener.com/quote/stock/OLIVE-RESOURCE-CAPITAL-IN-49477980/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-13T12:05:01Z",
            "content": "<table><tr><td>Sales 2022 </td><th>\r\n -4.13 M\r\n-2.99 M\r\n </th><td>Sales 2023 *</td><th>\r\n -\r\n </th><td>Capitalization</td><th>\r\n 4.43 M\r\n3.21 M\r\n </th></tr><tr><td>Net income 2022 </td><th>\r\n -3.00 M\u2026 [+4278 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "HC Wainwright Research Analysts Lower Earnings Estimates for Arbutus Biopharma Co. (NASDAQ:ABUS)",
            "description": "Arbutus Biopharma Co. (NASDAQ:ABUS \u2013 Free Report) \u2013 Equities research analysts at HC Wainwright decreased their FY2023 earnings estimates for Arbutus Biopharma in a research report issued on Wednesday, November 8th. HC Wainwright analyst E. Arce now anticipat\u2026",
            "url": "https://www.etfdailynews.com/2023/11/10/hc-wainwright-research-analysts-lower-earnings-estimates-for-arbutus-biopharma-co-nasdaqabus/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/arbutus-biopharma-corporation-logo.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-10T12:38:49Z",
            "content": "Arbutus Biopharma Co. (NASDAQ:ABUS \u2013 Free Report) \u2013 Equities research analysts at HC Wainwright decreased their FY2023 earnings estimates for Arbutus Biopharma in a research report issued on Wednesda\u2026 [+3554 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Complement 3 Glomerulopathy Market to Witness an Upsurge in Growth by 2023, Predicts DelveInsight | Key Companies to Watch - Novartis, Apellis, NovelMed, Amyndas, Arrowhead",
            "description": "The dynamics of the complement 3 glomerulopathy market are anticipated to change in the coming years owing to the improvement in the research and development activities so that the complement 3 glomerulopathy market will comprise efficient treatment options. \u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/06/2774408/0/en/Complement-3-Glomerulopathy-Market-to-Witness-an-Upsurge-in-Growth-by-2023-Predicts-DelveInsight-Key-Companies-to-Watch-Novartis-Apellis-NovelMed-Amyndas-Arrowhead.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2023-11-06T18:00:00Z",
            "content": "New York, USA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Complement 3 Glomerulopathy Market to Witness an Upsurge in Growth by 2023, Predicts DelveInsight | Key Companies to Watch - Novartis, Apellis, NovelM\u2026 [+14559 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Future Market Insights Global and Consulting Pvt. Ltd.",
            "title": "Use of AI and ML, Cloud Technology, Digital Therapeutics, and Blockchain Technology Create Significant Opportunities in Pharmaceutical Manufacturing Equipment Market Says FMI",
            "description": "Pharmaceutical Manufacturing Equipment Market Soars to US$ 27.3 Billion by 2033 with 6.4% CAGR. Lyophilizer Segment is Expected to be Dominant in Pharmaceutical Equipment Market Over the Forecast Period. North America has been Dominant in the Pharmaceutical E\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/07/2774773/0/en/Use-of-AI-and-ML-Cloud-Technology-Digital-Therapeutics-and-Blockchain-Technology-Create-Significant-Opportunities-in-Pharmaceutical-Manufacturing-Equipment-Market-Says-FMI.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/915d2f9c-7dc6-40c7-995c-2ba168208baa",
            "publishedAt": "2023-11-07T10:00:00Z",
            "content": "NEWARK, Del, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The global pharmaceutical manufacturing equipment market size is likely to jump from US$ 14.7 billion in 2023 to US$ 27.3 billion by 2033. The market is\u2026 [+7178 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "ADC Therapeutics SA",
            "title": "ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates",
            "description": "3Q 2023 ZYNLONTA\u00ae1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions",
            "url": "https://www.globenewswire.com/news-release/2023/11/07/2774888/0/en/ADC-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html",
            "urlToImage": "https://ml-eu.globenewswire.com/Resource/Download/42234478-810e-48c2-aadd-36edac51810d",
            "publishedAt": "2023-11-07T12:00:00Z",
            "content": "3Q 2023 ZYNLONTA\u00ae1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions\r\nOperating expenses decre\u2026 [+36678 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "PDS Biotechnology Corporation",
            "title": "PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
            "description": "PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS Biotech\u201d or \u201cCompany\u201d), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, a\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/12/04/2790507/37149/en/PDS-Biotechnology-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/e2e7d124-dbd4-4140-9cc5-449d3488a902",
            "publishedAt": "2023-12-04T21:50:00Z",
            "content": "PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or Company), a clinical-stage immunotherapy company developing a growing pipeline of targe\u2026 [+7340 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Comparing Pfizer (NYSE:PFE) and MacroGenics (NASDAQ:MGNX)",
            "description": "Pfizer (NYSE:PFE \u2013 Get Free Report) and MacroGenics (NASDAQ:MGNX \u2013 Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability\u2026",
            "url": "https://www.etfdailynews.com/2023/11/27/comparing-pfizer-nysepfe-and-macrogenics-nasdaqmgnx/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/macrogenics-inc-logo.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-27T17:06:41Z",
            "content": "Pfizer (NYSE:PFE \u2013 Get Free Report) and MacroGenics (NASDAQ:MGNX \u2013 Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the str\u2026 [+6703 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Visiongain Reports Ltd",
            "title": "Stem Cell Technologies and Applications market is projected to grow at a CAGR of 8.7% by 2033: Visiongain",
            "description": "Visiongain has published a new report entitled Stem Cell Technologies and Applications Market Report 2023-2033: Forecasts by Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), by Cell Source (Adipose Tissue-derived MSCs, Bone Marrow-derived MS\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/07/2775318/0/en/Stem-Cell-Technologies-and-Applications-market-is-projected-to-grow-at-a-CAGR-of-8-7-by-2033-Visiongain.html",
            "urlToImage": "https://ml-eu.globenewswire.com/Resource/Download/6bdb779b-409b-453a-a1ac-5548f5b2a98e",
            "publishedAt": "2023-11-07T15:47:00Z",
            "content": "Visiongain has published a new report entitled Stem Cell Technologies and Applications Market Report 2023-2033: Forecasts by Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), by Cell\u2026 [+19278 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Transparency Market Research",
            "title": "Syringes Market Size is Anticipated to Acquire USD 6.9 billion by 2031 | TMR (Analysis, Growth, Demand, Share, Outlook)",
            "description": "As the aging population and number of diseases increase, the demand for syringes in Europe is expected to increase. As the aging population and number of diseases increase, the demand for syringes in Europe is expected to increase.",
            "url": "https://www.globenewswire.com/news-release/2023/11/17/2782437/32656/en/Syringes-Market-Size-is-Anticipated-to-Acquire-USD-6-9-billion-by-2031-TMR-Analysis-Growth-Demand-Share-Outlook.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/27b21b27-620b-4cae-8360-605a9662092b",
            "publishedAt": "2023-11-17T10:00:00Z",
            "content": "Wilmington, Delaware, United States, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The syringes market was worth US$ 4 billion in Europe in 2021. From 2022 to 2031, it is proj\u2026 [+8348 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Analyzing AnaptysBio (NASDAQ:ANAB) and Imunon (NASDAQ:IMNN)",
            "description": "Imunon (NASDAQ:IMNN \u2013 Get Free Report) and AnaptysBio (NASDAQ:ANAB \u2013 Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations\u2026",
            "url": "https://www.etfdailynews.com/2023/11/12/analyzing-anaptysbio-nasdaqanab-and-imunon-nasdaqimnn/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/anaptysbio-inc-logo.jpg?v=20221207150520&w=240&h=240&zc=2",
            "publishedAt": "2023-11-12T11:22:41Z",
            "content": "Imunon (NASDAQ:IMNN \u2013 Get Free Report) and AnaptysBio (NASDAQ:ANAB \u2013 Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based\u2026 [+5026 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "QHSLab (OTCMKTS:USAQ) & Haemonetics (NYSE:HAE) Head to Head Contrast",
            "description": "QHSLab (OTCMKTS:USAQ \u2013 Get Free Report) and Haemonetics (NYSE:HAE \u2013 Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnin\u2026",
            "url": "https://www.etfdailynews.com/2023/11/19/qhslab-otcmktsusaq-haemonetics-nysehae-head-to-head-contrast/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/haemonetics-co-logo.png?v=20221117093105&w=240&h=240&zc=2",
            "publishedAt": "2023-11-19T13:02:42Z",
            "content": "QHSLab (OTCMKTS:USAQ \u2013 Get Free Report) and Haemonetics (NYSE:HAE \u2013 Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the stre\u2026 [+5845 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "SPHERICAL INSIGHTS LLP",
            "title": "Global HPV Testing and Pap Test Market Size To Worth USD 11.63 Billion By 2032 | CAGR of 13.6%",
            "description": "The Global HPV Testing and Pap Test Market Size was valued at USD 3.25 Billion in 2022 and the Worldwide HPV Testing and Pap Test Market Size is expected to reach USD 11.63 Billion by 2032, according to a research report published by Spherical Insights & Cons\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/21/2784248/0/en/Global-HPV-Testing-and-Pap-Test-Market-Size-To-Worth-USD-11-63-Billion-By-2032-CAGR-of-13-6.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/b27a94e8-407e-46ae-a5c2-47bb2a1c8a2e",
            "publishedAt": "2023-11-21T16:30:00Z",
            "content": "New York, United States, Nov. 21, 2023 (GLOBE NEWSWIRE) -- The Global HPV Testing and Pap Test Market Size is to grow from USD 3.25 Billion in 2022 to USD 11.63 Billion by 2032, at a Compound Annual \u2026 [+10173 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Future Market Insights Global and Consulting Pvt. Ltd.",
            "title": "Chronic Wound Care Market to Reach US$ 25,042.5 Million by 2033 Amid Need for Quick Healing and Shorter Hospital Stays | Future Market Insights, Inc.",
            "description": "The increasing adoption of active therapies is expected to contribute to the chronic wound care market's growth in the forecast period. Future Market Insights presents this information in their report titled \"Global Chronic Wound Care Market, 2023 to 2033\". T\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/28/2786766/0/en/Chronic-Wound-Care-Market-to-Reach-US-25-042-5-Million-by-2033-Amid-Need-for-Quick-Healing-and-Shorter-Hospital-Stays-Future-Market-Insights-Inc.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/915d2f9c-7dc6-40c7-995c-2ba168208baa",
            "publishedAt": "2023-11-28T11:30:00Z",
            "content": "NEWARK, Del, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The global chronic wound care market was valued at US$ 16,689.3 million in 2022 and is anticipated to exhibit a CAGR of 3.8% from 2023 to 2033. It is pr\u2026 [+10363 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "InvestorsObserver"
            },
            "author": "InvestorsObserver",
            "title": "Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs",
            "description": "Antengene to Host 2023 R&amp;D Day and Discuss Key Data with KOLs           Antengene to Host 2023 R&amp;D Day and Discuss Key Data with KOLs     PR Newswire             During the event,&#xA0;Antengene will review promising data of its R&amp;D pipelin...",
            "url": "https://www.investorsobserver.com/news/qm-pr/4559238514256122",
            "urlToImage": "https://s3.amazonaws.com/images.investorsobserver.com/io-logo-800x450.jpg",
            "publishedAt": "2023-11-07T19:30:00Z",
            "content": "<ul><li>\r\n During the event,\u00a0Antengene will review promising data of its R&amp;D pipeline, including\r\nATG-031 (anti-CD24 monoclonal antibody), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Clau\u2026 [+7979 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "PDS Biotechnology Corporation",
            "title": "PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update",
            "description": "PRINCETON, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS Biotech\u201d or the \u201cCompany\u201d), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease va\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/14/2779977/37149/en/PDS-Biotech-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/e2e7d124-dbd4-4140-9cc5-449d3488a902",
            "publishedAt": "2023-11-14T12:30:00Z",
            "content": "<ul><li>Announced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive cancer patients; published median overall survival of 7-11 m\u2026 [+30365 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Polaris Market Research & Consulting LLP",
            "title": "Global Protein A Resin Market Share Projected to be Worth USD 2,854.41 Million By 2032, at 9.4% CAGR Increase: Polaris Market Research",
            "description": "Global protein A resin market size & share is currently valued at USD 1,168.78 Million in 2022 and is anticipated to generate an estimated revenue of USD 2,854.41 Million by 2032, according to the latest study by Polaris Market Research. Besides, the report n\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/20/2783158/0/en/Global-Protein-A-Resin-Market-Share-Projected-to-be-Worth-USD-2-854-41-Million-By-2032-at-9-4-CAGR-Increase-Polaris-Market-Research.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/cf0a808d-3703-43f4-9b34-ec72345f8585",
            "publishedAt": "2023-11-20T12:50:00Z",
            "content": "New York, NY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Polaris Market Research has published a recent study report titled \"Protein A Resin Market Share, Size, Trends, Industry Analysis Report, By Type (Reco\u2026 [+13667 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Vantage Market Research",
            "title": "Multiple Sclerosis Drugs Market Size & Share to Surpass $34.36 Billion by 2030 | Vantage Market Research",
            "description": "WASHINGTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Global Multiple Sclerosis Drugs Market achieved a valuation of $25.90 Billion in 2022 and is anticipated to exceed $34.36 Billion by 2030, reflecting a compounded annual growth rate (CAGR) of 3.60% during the \u2026",
            "url": "https://www.globenewswire.com/news-release/2023/12/01/2789206/0/en/Multiple-Sclerosis-Drugs-Market-Size-Share-to-Surpass-34-36-Billion-by-2030-Vantage-Market-Research.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/b992ad70-52a5-4308-9ec3-ec32ebfecaee",
            "publishedAt": "2023-12-01T11:29:00Z",
            "content": "WASHINGTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Global Multiple Sclerosis Drugs Market achieved a valuation of $25.90 Billion in 2022 and is anticipated to exceed $34.36 Billion by 2030, reflecting\u2026 [+12428 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Renaissance Technologies LLC Sells 774,244 Shares of Incyte Co. (NASDAQ:INCY)",
            "description": "Renaissance Technologies LLC decreased its holdings in Incyte Co. (NASDAQ:INCY \u2013 Free Report) by 13.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,828,189 shar\u2026",
            "url": "https://www.etfdailynews.com/2023/11/29/renaissance-technologies-llc-sells-774244-shares-of-incyte-co-nasdaqincy/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/incyte-co-logo.png?v=20221104071538&w=240&h=240&zc=2",
            "publishedAt": "2023-11-29T18:23:21Z",
            "content": "Renaissance Technologies LLC decreased its holdings in Incyte Co. (NASDAQ:INCY \u2013 Free Report) by 13.8% during the second quarter, according to the company in its most recent disclosure with the Secur\u2026 [+5267 chars]"
        }
    ]
}